Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex

10-Jul-2009 - USA

Mylan Inc. announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bicalutamide Tablets, 50 mg.

Bicalutamide Tablets are the generic version of AstraZeneca's prostate cancer treatment Casodex®, which had total U.S. sales of approximately $322 million for the 12 months ending March 31 for the same strength, according to IMS Health. Mylan has begun to ship this product.

Currently, Mylan has 118 ANDAs pending FDA approval representing $82.8 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $16.7 billion in annual brand sales, according to IMS Health.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Novel regulator inhibits toxic protein aggregates in Huntington's disease

Research demonstrates millions of plastic particles exist in cosmetic products

Research demonstrates millions of plastic particles exist in cosmetic products

MDxHealth Receives 2011 European Molecular Diagnostics for Oncology Technology Leadership Award

Allogeneic stem cell transplantation in non-Hodgkin lymphoma: benefit remains unclear

Galapagos expands strategic alliance in metabolic disease with Merck & Co., Inc. - Total alliance milestones more than double to over €400 million, plus royalties on worldwide sales

Dharmacon Named Best Reagent Company at RNAi-2004-Boston Meeting on RNA

to-BBB starts manufacturing collaboration with TTY Biopharm for brain cancer treatment

Marine biomedicine researchers decode structure of promising sea compound - Novel natural product yielding potential new ways to fight diseases

The Medical Research Council and GATC Biotech sign Sequencing Contract

High-fiber diet linked to reduced risk of heart disease in night shift workers - It is thought that the mechanism works via the gut flora and lipid reduction

High-fiber diet linked to reduced risk of heart disease in night shift workers - It is thought that the mechanism works via the gut flora and lipid reduction

Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.

Heart disease specialists meet Spanish footballers to develop tools for detecting sudden death syndrome - Applied Biosystems hosts first symposium on sudden death in football players and other European athletes